Significant dissociation of brain and plasma kinetics with antipsychotics

Molecular Psychiatry

Volumn 7, Issue 3, 2002, Pages 317-321

  Tauscher, J ^a,b   Jones, C ^a   Remington, G ^a   Zipursky, R B ^a   Kapur, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotics; Dopamine receptors; Pharmacokinetics; Positron emission tomography; Receptor occupancy; Schizophrenia; Serotonin receptors

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; REGRESSION ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD-BRAIN BARRIER; BRAIN; CARBON RADIOISOTOPES; CLONAZEPAM; CORPUS STRIATUM; FEMALE; HALF-LIFE; HUMANS; KINETICS; MALE; PIRENZEPINE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; REFERENCE VALUES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 85047698394     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001009     Document Type: Article

References (22)

1. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
2. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers
3. Antipsychotic drug doses and neuroleptic/dopamine receptors
4. Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action
5. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
6. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects
7. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
8. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels
9. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings
10. 2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients
11. Olanzapine. Pharmacokinetic and pharmacodynamic profile
12. The pharmacokinetics of risperidone in humans: A summary
13. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
14. Pharmacokinetics of risperidone in chronic schizophrenic patients
15. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
16. Pharmacokinetics and tissue distribution of olanzapine in rats
17. 2 receptor occupancy
18. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
19. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
20. Simplified reference tissue model for PET receptor studies
21. Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry
22. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography